KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Ingredients (ALTO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Alto Ingredients (ALTO) over the last 15 years, with Q3 2025 value amounting to $5.0 million.

  • Alto Ingredients' Change in Accured Expenses rose 57805.34% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 39570.79%. This contributed to the annual value of $10.0 million for FY2024, which is 17926.56% up from last year.
  • According to the latest figures from Q3 2025, Alto Ingredients' Change in Accured Expenses is $5.0 million, which was up 57805.34% from $838000.0 recorded in Q2 2025.
  • Alto Ingredients' 5-year Change in Accured Expenses high stood at $31.2 million for Q4 2022, and its period low was -$30.5 million during Q3 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$875000.0 (2023), whereas its average is $1.8 million.
  • As far as peak fluctuations go, Alto Ingredients' Change in Accured Expenses tumbled by 106633.51% in 2022, and later surged by 179760.0% in 2024.
  • Over the past 5 years, Alto Ingredients' Change in Accured Expenses (Quarter) stood at $4.7 million in 2021, then soared by 558.93% to $31.2 million in 2022, then plummeted by 102.81% to -$875000.0 in 2023, then skyrocketed by 1797.6% to $14.9 million in 2024, then tumbled by 66.27% to $5.0 million in 2025.
  • Its Change in Accured Expenses stands at $5.0 million for Q3 2025, versus $838000.0 for Q2 2025 and -$3.6 million for Q1 2025.